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Background & Aims: Sorafenib is the recommended treatment for patients with advanced 
hepatocellular carcinoma (HCC). However, radioembolization (TARE) of HCC provides 
encouraging results both in terms of survival and capability to rescue unresectable tumors to surgery. 
This study evaluates the outcome reached with TARE and sorafenib in patients with HCC and intra-
hepatic portal vein tumor thrombosis (PVTT). 
Methods: Sixty-five patients with HCC and intra-hepatic PVTT treated in five Italian hospitals 
between 2012 and 2018 were included in the analysis. Exclusion criteria were any previous treatment, 
extension of PVTT to the main portal tract and extrahepatic involvement. Propensity score and 
Bayesian analysis were performed. 
Results: Forty-one patients received TARE and 24 sorafenib. Eleven patients were rescued to 
curative-intent surgery (3 liver transplant and 8 hepatectomy), 10 with TARE and 1 with sorafenib; 
TARE was significantly more effective than sorafenib in downstaging patients to surgery providing 
a mean survival of 54 months. In the 54 patients without downstaging after treatment, 31 treated with 
TARE and 23 with sorafenib, median survival was 20 months and 9 months respectively (p=0.001), 
with different 1, 2- and 3- years OS rates (64%, 43% and 37% vs 39%, 13% and 0%). Both propensity 
 
 
score and Bayesian model averaging confirmed an improvement in overall survival in TARE group 
compared to sorafenib treatment. 
Conclusions: TARE was more effective than sorafenib in downstaging patients to surgery providing 
a significant improvement in survival. Even in patients who were not rescued to surgery, survival 
appeared to be superior in TARE group.  
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Introduction 
Hepatocellular carcinoma (HCC) is the most frequent primary malignant liver tumor, and it represents 
the fourth leading cause of cancer-related death.(1,2) Despite recommended surveillance in at-risk 
patients, a high number of tumors are recognized at an advanced stage, when cure is no longer 
possible.(3) Portal vein tumor thrombosis (PVTT) develops in more than 30% of HCC patients during 
the disease course being a parameter of aggressiveness and a strong negative prognostic factor,(4–7) 
ranking the disease at an advanced stage conforming to the Barcelona Clinic Liver Cancer 
classification (BCLC).(2) 
Sorafenib, an oral multikinase inhibitor, is the worldwide recommended therapy for advanced 
HCC.(2,8) Systemic treatment with sorafenib was found to stabilize disease progression by its action 
on cell growth.(9) Moreover, sorafenib extend life expectancy but is not effective in shrinking tumors 
and a decrease in dose or interruption are often needed for adverse effects.(10–12) 
Transarterial radioembolization (TARE) is a loco-regional technique which consists in the infusion, 
through the hepatic artery, of microspheres carrying an yttrium-90 isotope, which deliver high energy 
of beta-radiation into the tumor. TARE has been reported to induce a significant decrease in tumor 
size with a low-grade toxicity, prolonging time to progression and survival.(13–15) TARE can be 
used with safety in patients with portal vein thrombosis (PVT) for its low risk of liver ischemia(16,17) 
 
 
and it has been successfully performed in downstaging strategy in liver transplantation or resective 
surgery setting.(18–20) 
Recently, two randomized trials, SARAH and SIRveNIB, did not show better survival of TARE over 
sorafenib in patients with advanced HCC.(11,21) The failure could be partially explained by the 
inclusion of a large share of patients with PVTT extended to the major portal trunk in the TARE arm, 
since it has recently been reported that the extension of PVTT to the main portal trunk makes TARE 
treatment futile.(22) Therefore, the scope of our work was to retrospectively investigated the outcome 
of patients treated with TARE or sorafenib as first-line therapy, focusing on patients with HCC and 
PVTT limited to the intra-hepatic branches.  
 
Patients and methods 
 
Patients 
This retrospective study consisted of consecutive HCC patients treated with TARE or sorafenib  
between 2012 and 2018 at five large hospitals in Northwestern Italy: University Hospital “Città della 
Salute e della Scienza” Turin, Mauriziano Hospital Turin, Santa Croce e Carle General Hospital 
Cuneo, Regional Hospital of Aosta Valley Aosta, University Hospital “Maggiore della Carità” 
Novara. The treatment protocols were authorized by Institutional Ethical Committees and informed 
consent was obtained by all patients. 
Inclusion criteria were naïve patients with Child-Pugh A liver cirrhosis, Eastern Cooperative 
Oncology Group Performance Status ECOG 0 or 1 and HCC with neoplastic portal vein thrombosis 
limited to the intra-hepatic branches.  Neoplastic portal vein thrombosis was classified conforming to 
the Liver Cancer Study Group of Japan (LCSGJ):(23)VP1 (distal to but not in second-order branches 
of the portal vein), VP2 (in second-order branches of the portal vein), VP3 (in first-order branches of 
the portal vein), VP4 (tumor thrombus in the main trunk of the portal vein and/or contralateral to the 
trunk). Exclusion criteria were extra-hepatic localizations, presence of non-neoplastic portal vein 
 
 
thrombosis, presence of neoplastic portal vein thrombosis VP4 and any previous and subsequent 
therapy. Histology or non-invasive imaging criteria were used for the diagnosis of HCC.(24) 
Differentiation of portal vein thrombosis from tumorous portal vein infiltration was made with great 
precision by contrast-enhanced imaging techniques.(25–28) 
 
TARE procedure 
All patients underwent a standardized workup before treatment; an angiographic study was performed 
to assess collateral vessels supplying  extrahepatic organs and subsequently 150 MBq of technetium-
99-labeled macroaggregated albumin (99-Tc-MAA) were infused to evaluate  the vascular 
distribution of the microspheres. A total body planar image and a photon emission computed 
tomography (SPECT-CT) were acquired. In order to administer the optimal tumoricide dose and not 
to exceed 30 Gy to the lung and 40 Gy to the surrounding liver parenchyma, activities were 
determined using the multicompartimental MIRD model. (29,30) 
Transarterial radioembolization was performed, within two weeks, according to the manufacturer 
guidelines using either yttrium-90 resin (SIR-Spheres; Sirtex Medical Europe, GmbH) or yttrium-90 
glass (TheraSphere, BTG International, London, UK) microspheres.(31)  
 
Sorafenib treatment 
Sorafenib was started at the recommended dose of 400 mg twice a day, with dose modifications or 
interruption according to adverse effects (AEs), graded in agreement with the National Cancer 
Institute Common Toxicity Criteria (CTCAE3.0). 
 
Follow up and response  
Liver function, serum α-fetoprotein (AFP) and physical examinations were performed every month 
for the first 6 months and then every 3 months. Contrast enhanced computed tomography (CT) was 
performed at second month after treatment and every 3 or 6 months according to the clinical course 
 
 
of the disease. Treatment response was evaluated according to the response evaluation criteria in solid 
tumors (mRECIST) and the EASL criteria on vascular enhancement.(32,33)  
 
Statistical analysis  
Continuous variables were presented as median and interquartile range (IQR); categorical variables 
were expressed with number and percentage. TARE patients were compared with sorafenib using 
Mann-Whitney or Fisher’s exact tests, as appropriate. The follow-up time was considered from the 
start of therapy with TARE or sorafenib until the date of death or last visit. The follow-up time was 
also censored at December 2019. Kaplan-Meier survival estimate were used to evaluate the overall 
survival in the propensity score analysis, the significance was assessed using Log-rank test. The effect 
of the outcome was expressed as Hazard Ratio (HR), Schoenfeld test was performed for test the 
proportional hazard assumption. P-values below 0.05 were considered statistically significant. To 
adjust for potential patient selection bias, attributable to non-randomized assignment of treatment, a 
propensity score analysis matching (PSM) and weighting (IPTW) was applied. Four independent 
prognostic factors were considered in the model: PVTT type 3, number of lesions, alpha-fetoprotein 
levels and disease progression time. Since both PSM and IPTW do not consider the best model of 
variable selection and residual imbalance between groups due to the small number of patients, a 
further analysis based on Bayesian Model Averaging (BMA) was performed on all patients. Hazard 
Ratio (HR) and the probability of a significant result provided the measure of the size of the 
association(34). (34). Probabilities greater than 95% were considered an indication of strong 
association, probabilities between 75 and 95% a positive indication of association and probabilities 
smaller than 75% were considered a weak evidence of an effect.(35) R version 3.6.1 was used to 




Overall, 65 out of 286 patients with HCC and PVTT were recruited in the study. Forty-one were 
treated with TARE and 24 with sorafenib as first-line treatment. Twenty-three were treated with 
yttrium-90 resin microspheres and 18 with yttrium-90 glass microspheres. Several patients treated 
with sorafenib were excluded from the analysis due to previous treatments or due to the invasion of 
the PVTT in the main trunk. 
Eleven patients were rescued to surgery: three patients underwent orthotopic liver transplantation 
(OLT) and 8 major right hepatectomy. Ten patients obtained a downstaging with TARE and 1 with 
sorafenib. Eight patients (73%) were still alive at the end of follow-up. Mean survival of the 
downstaging group was 54 months. Because of the small sample size of downstaged patients, no 
statistical inferential analysis was performed in this group. 
Baseline demographic properties of the patients are listed in Table 1. Gender male predominance and 
higher MELD score in the sorafenib group were the only significant differences. 
Median overall survival was 20.3 months (95% CI: 10.8–50.0) versus 9.1 months (95% CI: 5.8–18.5) 
in TARE versus sorafenib patients, respectively (p=0.001). 
The 1, 2 and 3-year OS rates were 64.5%, 42.6% and 37.3% vs 39.1%, 13.0% and 0% in TARE and 
sorafenib patients, respectively (Figure 1). At Univariate Cox model patients undergoing TARE had 
a longer survival in comparison to patients receiving sorafenib (HR 0.359; 95% CI:0.190–0.678; 
p=0.002).  
The propensity matched score analysis (23 TARE vs 23 sorafenib patients) confirmed a median 
survival of 22.4 months (95% CI 10.8-NA) in the TARE group and 9.1 months (95% CI 5.8-18.5) in 
the sorafenib group (p=0.002). The 1, 2 and 3- year OS rates in TARE and sorafenib group were 
65.2%, 43.1% and 34.5% vs 39.1%, 13% and 0% respectively (Figure 2). Univariate Cox model 
confirmed the effect of the TARE on OS (HR 0.341; 95% CI:0.168–0.691; p=0.003).  
At propensity score weighting, performed on all treated patients (n=31 TARE vs n=23 sorafenib), 
overall median survival resulted 20.3 months (95% CI: 10.8–50.0) in TARE and 10.5 months (95% 
 
 
CI: 5.7–19.4) in sorafenib group (p=0.003). The 1, 2 and 3-year OS rates in TARE and sorafenib 
group were 64.5%, 42.6% and 37.3% vs 40.5%, 16.4% and 0% respectively (Figure 3). Univariate 
Cox model confirmed the effect of the TARE on OS (HR 0.381; 95% CI:0.201–0.720; p=0.003) 
(Table 2).  
An additional analysis using Bayesian Model Averaging (BMA) was conducted on the entire cohort. 
As shown in Table 3 only TARE showed a strong correlation with the survival (HR 0.43 with a 






The clinical value of trans-arterial radioembolization with yttrium-90 microspheres in the 
management of advanced hepatocellular carcinoma is a matter for debate. Growing evidence suggest 
the role of radioembolization as a safe and efficient treatment for unresectable HCC.(17,37,38) 
Nevertheless, for many years randomized controlled trials have not been conducted, probably due to 
the intrinsic complexity of the procedure, requiring a multidisciplinary skilled team, that limits the 
spread of radioembolization. 
Our retrospective multicenter study, focused on a highly selected cohort of patients with locally 
advanced hepatocellular carcinoma and PVTT limited to the intra-hepatic branches, showed that 
radioembolization was more performing than sorafenib in terms of survival and downstaging to 
further surgery intervention. 
The 1, 2 and 3-year OS rates in TARE and sorafenib group were 64.5%, 42.6% and 37.3% vs 39.1%, 
13.0% and 0%, respectively and overall median survival time was 2 time higher in TARE compared 
to sorafenib patients (20.3 months vs 9.1). A significant improvement of survival in TARE group 
(HR 0.359; 95% CI:0.190 0.678, p=0.002) was demonstrate in all survival analysis. 
Recently, two randomized controlled trials, the “Selective Internal Radiation Therapy Versus 
Sorafenib” (SIRveNIB) trial(21) and the “SorAfenib versus Radioembolization in Advanced 
Hepatocellular carcinoma” (SARAH)(11), failed to demonstrate the superiority of radioembolization 
versus sorafenib. Similar median overall survival was observed in both groups: 8.8 months versus 10 
months in the SIRveNIB trial and 8.0 months versus 9.9 months in the SARAH trial for TARE and 
sorafenib, respectively. In our opinion, the inclusion of a significant proportion of patients with 
neoplastic invasion of the main portal trunk in these two trials may have adversely affected the 
outcome of the patients treated with TARE. Moreover, a recent study shows that PVTT extension, 
bilirubin level and tumor burden have an independent effect on long-term survival of TARE, while 




Furthermore, our study showed that TARE resulted more performing than sorafenib in 
downsizing/downstaging patients to a surgical curative-intent treatment: 10 of 41 patients were 
rescued to surgery with TARE, while only 1 of 24 with sorafenib. 73% (8/11 patients) were still alive 
at the end of the follow-up and the mean survival time was 54 months. It is important to underline 
that, at baseline, patients rescued to surgery have a lower AFP level, a lower number of lesions and a 
lower extension of PVTT compared to the others. These data should be taken in account when 
consider a treatment for patient with advanced HCC but have to be validated by more extensive 
studies. 
Main significant biases of our study were the low number of enrolled patients and the retrospective 
collection of the data. Due to the restricted inclusion criteria many patients treated with sorafenib 
were excluded from the analysis, however the two groups of treatment at baseline were 
demographically and clinically similar.  To overcome these limitations, we used the propensity score 
method to evaluate the impact of radioembolization and sorafenib on overall survival and Bayesian 
analysis to analyze the effect of different variables on the outcome. Both propensity score matched 
analysis and propensity score weighted analysis concurred to show an improvement in overall 
survival in TARE group in comparison to systemic treatment. These data indicate TARE as the best 
performing treatment in selected patients (HR 0.341; 95% CI:0.168–0.691; p=0.003 and HR 0.381; 
95% CI:0.201–0.720; p=0.003 respectively). Similarly, Bayesian Model Averaging (BMA) analysis 
demonstrated that patients treated with TARE had a higher overall survival than sorafenib (HR 0.43 
with 95% credible interval: 0,19-0,99), with a high probability of significant association and high 
probability of inclusion (90.7%).  
Another possible limitation of our study is related to the adoption of two different devices for 
delivering selective internal radiation to the tumor; in fact, the two microsphere products are slightly 
different when it comes to number of particles, density, size and method of infusion.  
 
 
However, it must be considered that in literature the survival and radiological response reported in 
HCC patients are similar for the two techniques. (39,40) In our opinion, we believe that the outcome 
is determined more by the accurate dosimetric study than by the device used. 
In Advanced HCC patients the choice of the correct therapy is always a big challenge and many 
aspects have to be considered such as quality of life, costs and local availability. However, even if in 
this study we did not analyzed these data, a recent study compared cost of using radioembolization 
versus sorafenib and lenvatinib as primary treatment from the healthcare payer perspectives in Italy, 
France, Spain and UK, given the improved quality of life and the potential to rescue patients to 
curative therapies.(41) TARE resulted in cost reduction in all four states, even including the costs of 
curative treatment. Other studies were published in the past years supporting the same results.(42–
44) 
The therapeutic horizon of HCC is rapidly evolving and different immune-oncotherapeutic drugs, 
alone or in combination, recently showed encouraging results with regards to oncological response 
and therefore of downstaging capability to rescue to curative treatments.(45–48)  
The widespread adoption of these upcoming treatments would inevitably lead to an increase in the 
total oncologic cost, that could be difficult to bear for the healthcare system. 
In conclusion, our study showed that TARE can be considered as first option in selected patients with 
advanced HCC with branches portal vein tumor thrombosis and without extrahepatic disease; 
however, prospective studies are required to compare radioembolization with new upcoming 
immune-chemotherapeutic agents.   
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 Table 1. Baseline characteristics of patients by treatment 




Number of patients 23 31  11 
Age (years) 75.00 [62.00, 81.00] 73.00 [63.00, 82.00] 0.800 77.00 [68.50, 80.00] 
Male sex, n (%) 23 (100.0) 25 (80.6) 0.032 11 (100.0) 
Etiology, n (%) 
Viral 
13 (56.5) 21 (67.7) 0.569 8 (72.7) 
INR 1.07 [1.00, 1.30] 1.09 [1.00, 1.13] 0.218 1.07 [1.00, 1.16] 
Total bilirubin (mg/dl) 1.10 [0.70, 1.31] 0.90 [0.70, 1.05] 0.131 1.00 [0.85, 1.30] 
Albumin (g/dl) 38.00 [36.00, 40.00] 36.00 [35.00, 39.50] 0.280 36.00 [35.00, 38.50] 
Creatinine (mg/dl) 0.80 [0.68, 0.97] 0.80 [0.65, 0.90] 0.438 0.80 [0.66, 0.90] 
MELD score 9.00 [8.00, 10.00] 8.00 [7.00, 9.00] 0.035 9.00 [8.00, 9.50] 
Main tumor diameter 
(mm) 
48.00 [40.00, 70.00] 55.00 [36.50, 72.50] 0.955 70.00 [51.50, 80.00] 
Number of lesions, n (%) 
Unifocal 
7 (30.4) 10 (32.3) 1.000 4 (36.4) 
PVTT Type 3, n (%) 
 
15 (65.2) 14 (45.2) 0.175 1 (9.1) 
AFP (ng/ml) 907.00 [39.20, 2028.00] 326.00 [10.55, 1279.00] 0.416 24.00 [9.00, 343.50] 
AFP   400 (ng/ml), n (%) 13 (56.5) 14 (45.2) 0.583 3 (27.3) 
MELD, Model for End-stage Liver Disease; INR, International Normalized Ratio, AFP, Alpha-fetoprotein. 
1Comparison between patients treated with TARE and patients treated with sorafenib 
 
Table 2. TARE vs sorafenib Hazard ratio 
 Hazard Ratio Confidence interval 95% p-value 
No propensity score 0.359 0.190–0.678 p=0.002 
Propensity score matched 0.341 0.168–0.691 p=0.003 
Propensity score weighted 0.381 0.201–0.720 p=0.003 
 
Table 3. Bayesian model averaging results.  






95% Credible Interval 
AFP = < 400 0.87 0.690 29.50 0.50 1.48 
PVTT, Type 3 0.94 0.625 17.50 0.66 1.35 
Number of 
lesions > 1 1.02 0.568 11.20 0.79 1.32 
Progression  1.68 0.850 63.70 0.63 4.52 








Figure 1: Kaplan-Meier without Propensity Score  
Figure 2: Kaplan-Meier after Propensity Score Matching  
Figure 3: Kaplan-Meier after Propensity Score Weighting  
 
 
  
 
 
 
 
